A Review on Molecular Docking on HDAC Isoforms: Novel Tool for Designing Selective Inhibitors

Pharmaceuticals (Basel). 2023 Nov 22;16(12):1639. doi: 10.3390/ph16121639.

Abstract

Research into histone deacetylases (HDACs) has experienced a remarkable surge in recent years. These enzymes are key regulators of several fundamental biological processes, often associated with severe and potentially fatal diseases. Inhibition of their activity represents a promising therapeutic approach and a prospective strategy for the development of new therapeutic agents. A critical aspect of their inhibition is to achieve selectivity in terms of enzyme isoforms, which is essential to improve treatment efficacy while reducing undesirable pleiotropic effects. The development of computational chemistry tools, particularly molecular docking, is greatly enhancing the precision of designing molecules with inherent potential for specific activity. Therefore, it was considered necessary to review the molecular docking studies conducted on the major isozymes of the enzyme in order to identify the specific interactions associated with each selective HDAC inhibitor. In particular, the most critical isozymes of HDAC (1, 2, 3, 6, and 8) have been thoroughly investigated within the scope of this review.

Keywords: enzyme inhibition; histone deacetylases; interactions; isoforms; molecular docking.

Publication types

  • Review

Grants and funding

This research received no external funding.